Findings from Tulane University Provides New Data about Cancer (Bortezomib In Cancer Therapy: Mechanisms, Side Effects, and Future Proteasome Inhibitors).

A recent study from Tulane University explores the use of Bortezomib as a proteasome inhibitor in cancer therapy, particularly for multiple myeloma and mantle cell lymphoma. The research highlights the mechanisms of action of Bortezomib, such as inhibiting the 26S proteasome and modulating various cellular processes, while also acknowledging its limitations due to side effects like peripheral neuropathy and thrombotic microangiopathy. The study concludes by discussing the potential for next-generation proteasome inhibitors in cancer treatment. For more information, readers can refer to the article "Bortezomib In Cancer Therapy: Mechanisms, Side Effects, and Future Proteasome Inhibitors" published in Life Sciences. [Extracted from the article]